Main Business Income Exceeded RMB 6.4 Billion, 9 Major Products' Sales Over 100 Million

In 2011, Fosun Pharma overcame the adverse macro-environment of external economy, through focusing on the core pharmaceutical business, persisting in product innovation and management promotion, as well as adhering to the strategic development pattern of "endogenous growth, extensive expansion and integrated development", and its main business has remained fast growth trend.

During report period, Fosun Pharma's main business income reached RMB6.486 billion, a year-on year increase of 42.37%. Along with the robust sale force, Fosun Pharma's operating profit, total profit and net margin achieved major increase. The net profit of shareholders of its affiliated listed company totaled RMB1.166 billion, a year-on-year increase of 34.96%.

The fast growth of Fosun Pharma's performance is mainly attributed to its rapid expansion over pharmaceutical manufacturing business. During the report period, the revenue of Fosun Pharma's pharmaceutical business reached RMB3.867 billion, a year-on-year increase of 35.22%, and total profit of branches reached RMB746 million, a year-on-year increase of 50.32%, thanks to its years of pharmaceutical R&D and manufacturing development and also to the achievements of several successful mergers and acquisitions over recent years. Fosun Pharma's major products in therapeutic areas, such as metabolism, alimentary canal, cardiovascular system, central nerve system, blood system, and anti-infective, have retained its leading position in each market segment in China. The sales of 9 of its major products in the above areas are over RMB100 million, including Atuomolan

Share
© Publicnow - 2012